Current status of stereotactic body radiotherapy for the treatment of hepatocellular carcinoma

Jongmoo Park; Jae Won Park; Min Kyu Kang

doi:10.12701/yujm.2019.00269

Current status of stereotactic body radiotherapy for the treatment of hepatocellular carcinoma

Yeungnam Univ J Med. 2019 Sep;36(3):192-200. doi: 10.12701/yujm.2019.00269. Epub 2019 Aug 12.

Authors

Jongmoo Park¹, Jae Won Park², Min Kyu Kang¹

Affiliations

¹ Department of Radiation Oncology, School of Medicine, Kyungpook National University, Daegu, Korea.
² Department of Radiation Oncology, Yeungnam University College of Medicine, Daegu, Korea.

Abstract

Stereotactic body radiotherapy (SBRT) is an advanced form of radiotherapy (RT) with a growing interest on its application in the treatment of hepatocellular carcinoma (HCC). It can deliver ablative radiation doses to tumors in a few fractions without excessive doses to normal tissues, with the help of advanced modern RT and imaging technologies. Currently, SBRT is recommended as an alternative to curative treatments, such as surgery and radiofrequency ablation. This review discusses the current status of SBRT to aid in the decision making on how it is incorporated into the HCC management.

Keywords: Hepatocellular carcinoma; Image-guided radiotherapy; Radiotherapy; Stereotactic body radiotherapy.

Publication types

Review